Skip to main content
S&P 5007,520.93-0.38%DOW52,231.89-0.30%NASDAQ25,065.88-0.74%BTC$73,671.00-1.77%ETH$2,057.29-3.16%GOLD$4,059.70+0.73%OIL$86.26+0.26%
Smart Investors Daily
SID Premium
PR

NASDAQ · PROK

ProKidney Corp.

Healthcare · Biotechnology

$1.11

Down-$0.04 (-3.48%)

Updated Nov 11, 2026, 4:22 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
623.32M
P/E ratio
-4
Dividend yield
0.00%
52-week range
$0.87 – $2.95
Volume
733.34K
Avg. volume
1.98M

Price performance · PROK

PROK price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

PROK closed at $1.11 after 21 trading sessions, down 29.30% for the selected period.

Last close
$1.11
Period change
-29.30%
Period low
$1.07
Period high
$1.57
Daily close
View OHLC price history
PROK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$1.12$1.165$1.065$1.11733.34K
Nov 9, 2026$1.14$1.27$1.10$1.151.47M
Nov 6, 2026$1.05$1.1595$1.04$1.14950.92K
Nov 5, 2026$1.11$1.11$1.00$1.0651.17M
Nov 4, 2026$1.09$1.14$1.01$1.121.24M
Nov 3, 2026$1.105$1.13$1.00$1.071.54M
Nov 2, 2026$1.33$1.35$0.8702$1.127.3M
Oct 30, 2026$1.41$1.4594$1.29$1.2951.73M
Oct 29, 2026$1.51$1.53$1.43$1.47821.23K
Oct 28, 2026$1.47$1.595$1.46$1.521.5M
Oct 27, 2026$1.39$1.55$1.355$1.5151.37M
Oct 26, 2026$1.41$1.435$1.35$1.36761.68K
Oct 23, 2026$1.43$1.44$1.37$1.41535.23K
Oct 22, 2026$1.42$1.48$1.415$1.43584.48K
Oct 21, 2026$1.44$1.49$1.44$1.44601.29K
Oct 20, 2026$1.40$1.51$1.35$1.441.49M
Oct 19, 2026$1.35$1.41$1.35$1.395966.95K
Oct 16, 2026$1.43$1.4744$1.305$1.331.67M
Oct 15, 2026$1.44$1.485$1.42$1.4551.11M
Oct 14, 2026$1.54$1.57$1.41$1.472.13M
Oct 13, 2026$1.65$1.68$1.53$1.571.6M

Latest PROK news

The latest Smart Investors Daily articles mentioning PROK.

Stock researchCompany · Overview

PROK research

Overview

Company profile and research snapshot.

Company profile

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.67
Implied upside
—
Analysts
—
PROK recent ratings
DateFirmRatingTarget
Oct 28, 2026CitigroupBuy—
May 18, 2026HC Wainwright & Co.Buy—
Dec 16, 2025HC Wainwright & Co.Buy—
Jul 15, 2025UBSBuy—
Jul 14, 2025GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencelOne clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKid

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By